Cann reiterated their buy rating on shares of Epizyme, Inc. (NASDAQ:EPZM) in a report released on Thursday, November 2nd. They currently have a $26.00 price objective on the biopharmaceutical company’s stock.
“Epizyme’s loss per share of $0.63 was less than our estimated $(0.75). This primarily resulted from lower than estimated operating expense of $38.1 million compared to our estimated $44.5 million. Our outlook remains basically unchanged for 2018-2022.”,” Cann’s analyst commented.
EPZM has been the subject of a number of other reports. BidaskClub downgraded Epizyme from a sell rating to a strong sell rating in a report on Friday, July 28th. Jefferies Group LLC began coverage on Epizyme in a report on Wednesday, September 20th. They issued a buy rating and a $23.00 target price for the company. Royal Bank Of Canada set a $20.00 target price on Epizyme and gave the company a buy rating in a report on Saturday, August 5th. Zacks Investment Research raised Epizyme from a hold rating to a buy rating and set a $16.00 target price for the company in a report on Tuesday, July 18th. Finally, HC Wainwright reissued a buy rating on shares of Epizyme in a report on Monday, August 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of $22.67.
Epizyme (NASDAQ EPZM) traded up $0.05 during trading hours on Thursday, reaching $12.85. The company had a trading volume of 305,580 shares, compared to its average volume of 579,266. Epizyme has a 52-week low of $9.30 and a 52-week high of $20.45.
Epizyme (NASDAQ:EPZM) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.02. research analysts anticipate that Epizyme will post -2.23 EPS for the current year.
WARNING: This piece was reported by BBNS and is the sole property of of BBNS. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://baseballnewssource.com/markets/epizyme-inc-epzm-receives-buy-rating-from-cann/1751104.html.
In related news, insider Peter Tai-Ching Ho sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, August 24th. The stock was sold at an average price of $15.68, for a total value of $235,200.00. Following the sale, the insider now owns 22,228 shares of the company’s stock, valued at approximately $348,535.04. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director David M. Mott bought 200,000 shares of Epizyme stock in a transaction that occurred on Monday, September 18th. The stock was bought at an average cost of $15.25 per share, for a total transaction of $3,050,000.00. Following the purchase, the director now owns 6,000 shares in the company, valued at approximately $91,500. The disclosure for this purchase can be found here. Insiders have sold a total of 45,000 shares of company stock worth $733,950 in the last three months. Corporate insiders own 25.20% of the company’s stock.
A number of hedge funds have recently bought and sold shares of EPZM. Legal & General Group Plc lifted its stake in Epizyme by 8.9% in the 1st quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock valued at $165,000 after buying an additional 795 shares in the last quarter. UBS Asset Management Americas Inc. purchased a new position in shares of Epizyme during the 1st quarter worth $175,000. BB&T Securities LLC purchased a new position in shares of Epizyme during the 2nd quarter worth $181,000. Trexquant Investment LP purchased a new position in shares of Epizyme during the 2nd quarter worth $184,000. Finally, SG Americas Securities LLC lifted its stake in shares of Epizyme by 83.3% during the 2nd quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock worth $202,000 after purchasing an additional 6,072 shares during the period. 78.00% of the stock is currently owned by hedge funds and other institutional investors.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with our FREE daily email newsletter.